Background: We conducted a meta-analysis to review the available evidence
| INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with systemic inflammation that affects mainly synovial joints leading to tissues destruction, disability and excess of mortality. 1 The prevalence rate for RA in Western countries is approximately 0.5%-1% of the adult population. 2 Although the cause is still unknown, RA is thought to be the result of immune-mediated mechanisms triggered by environmental factors in subjects harbouring a genetically favourable substrate. 1, 2 Autoimmune response to post-translationally modified self-proteins (eg, citrullinated-peptides), innate and adaptive immune cells activation and production of pro-inflammatory cytokines (TNF-α, IL-1, and IL-6) are the pathophysiological hallmarks of the disease.
reactant levels and RF/ACPA positivity) show good sensitivity (0.59-0.95) and low/moderate specificity (0.34-0.96) for the diagnosis of RA. 5 Therefore, there is an ongoing need to develop measurable biomarkers that could facilitate early and accurate diagnosis of RA. Recently, several reports have suggested the potential utility of the neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR), as diagnostic biomarkers in RA [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and other rheumatic diseases. [18] [19] [20] A previous meta-analysis reported a significant association between NLR and PLR and RA. 21 However, the number of studies analysed was relatively low. 7, 11, 13 Therefore, we conducted an updated meta-analysis on a larger number of studies to investigate the association between NLR/PLR and RA.
| MATERIALS AND METHODS

| Search strategy, eligibility criteria and study selection
A systematic search of publications in the electronic databases PubMed, Web of Science and Scopus, from inception to January 2018, was conducted using the following terms and their combination: "rheumatoid arthritis," "NLR," "neutrophil to lymphocyte ratio," "PLR" and "platelet to lymphocyte ratio." Abstracts were screened independently by two investigators and, if relevant, full articles were reviewed. Eligibility criteria were as follows: (a) assessment of blood NLR and/or PLR, (b) comparison of human subjects with or without rheumatoid arthritis (case-control design), (c) English language and (d) full-text publications. The references of retrieved articles and reviews were also searched to identify additional studies. Data extraction and quality assessment were performed independently by two investigators. Any disagreement between the reviewers was resolved by a third investigator.
We used the Newcastle-Ottawa Scale (NOS) to assess the quality of each study. 22 The Newcastle-Ottawa scale evaluated the following components: selection of the cohort, comparability of cohorts on the basis of the design or analysis, how the exposure was ascertained, and how the outcomes of interest were assessed. Studies achieving a score of six or more were considered to be of high quality.
| Statistical analysis
Standardized mean differences (SMD) were used to construct forest plots of continuous data and to evaluate differences in NLR and PLR values between healthy controls and patients with RA. A P-value < 0.05 was considered statistically significant, and 95% confidence intervals (CIs) were reported. In one study, 6 the median and range values were extrapolated from graphs using the Graph Data Extractor software, in three studies 6-8 the mean and standard deviation values were extrapolated from the median and range as previously described, 23 and in two other studies 9,10 the mean and standard deviation values were extrapolated from the median and interquartile range (IQR) as previously reported. 24 Heterogeneity of SMD across studies was tested by using the Q statistic (significance level at P < 0.10). The I 2 statistic, a quantitative measure of inconsistency across studies, was also calculated (I 2 < 25%, no heterogeneity; I 2 between 25% and 50%, moderate heterogeneity; I 2 between 50% and 75%, high heterogeneity; and I 2 > 75%, extreme heterogeneity). 25, 26 Due to the high heterogeneity, a random-effects model was used to calculate the pooled SMD and corresponding 95% confidence intervals. Sensitivity analysis was conducted to investigate the influence of an individual study on the overall risk estimate, by sequentially excluding one study at a time. 27 To evaluate the presence of potential publication bias, the associations between study size and magnitude of effect were analysed by means of Begg's adjusted rank correlation test and Egger's regression asymmetry test at the P < 0.05 level of significance. 28, 29 We also performed the Duval and Tweedie "trim and fill" procedure 30 to identify and correct for funnel plot asymmetry arising from publication bias. The basis of the method is to (a) "trim" (remove) the smaller studies causing funnel plot asymmetry, (b) use the trimmed funnel plot to estimate the true "centre" of the funnel, then (c) replace the omitted studies and their missing "counterparts" around the centre (filling). This method provides an estimate of the number of missing studies and recalculates a pooled SMD including the filled studies. The effect of disease severity on SMD was assessed by separating studies in two groups using median CRP and ESR mean as the threshold for separation. Therefore, a given study was placed in the low CRP/ESR group if the study's patients' mean or median CRP/ESR was ≤ the CRP/ESR threshold value or alternatively in the high CRP and high ESR group if the study's patients' mean or median CRP/ESR was above the CRP/ESR threshold value.
Statistical analyses were performed using MedCalc for Windows, version 15.4 64 bit (MedCalc Software, Ostend, Belgium) and STATA 14 (STATA Corp., College Station, TX, USA). Our study followed the PRISMA statement regarding the reporting of systematic reviews and meta-analyses and EQUATOR guidelines. 31, 32 3 | RESULTS
| Literature search and study selection
A flow chart describing the screening process is presented in Figure 1 . We initially identified 217 potential relevant studies. A total of 192 studies were excluded after the initial screening because they were duplicates or irrelevant. After a full-text revision of 25 articles, 12 studies were excluded because they did not meet the inclusion criteria. Thus, thirteen studies were included in the meta-analysis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 33 The characteristics of these studies, published between 2015 and 2017, are presented in Table 1 .
| NLR and rheumatoid arthritis
A total of 1550 RA patients (477 males and 1073 females), and 1128 healthy controls (326 males and 802 females) were evaluated. Overall, the mean ± SD age of RA participants and controls was 52.1 ± 2.4 and 47.1 ± 1.7 years, respectively. C-reactive protein and ESR values in RA patients ranged between 1.1-38.6 mg/L and 16.8-108.41 mm/h, respectively, suggesting a high variability in disease severity. RA patients showed significantly higher NLR values when compared to controls ( Figure 2) .
Substantial heterogeneity between studies was observed (I 2 = 88%, P < 0.001). Thus, random-effects models were used. Overall, pooled results showed that NLR values were significantly higher in patients with RA (SMD = 0.79, 95% CI 0.55-1.03; P < 0.001). Sensitivity analysis showed that the corresponding pooled SMD values were not substantially altered, both in terms of direction and in terms of significance of the finding, when individual studies were removed (effect size ranged between 0.64 and 0.84, Figure 3 ), although the study of Fawzy et al 16 had a pronounced effect on the magnitude of the results. Moreover, funnel plot analysis showed that this same study influenced the graph symmetry ( Figure 3 ). Removal of this study provided an estimate level of 0.64 (95% CI: 0.49-0.80; P < 0.001; I 2 = 70.2%, P < 0.0001).
Bias analysis of the 12 remaining studies indicated the absence of publication bias (Begg P = 0.63 and Egger tests P = 0.88). Furthermore, no potential missing study was detected by the trim-and-fill method.
We investigated the effects of different disease severity (CRP ≤11 vs >11 mg/L and ESR ≤37 vs >37 mm/h, where 11 mg/L and 37 mm/h were the median values of CRP and ESR, respectively), as well as study types (retrospective or prospective) on SMD values.
Standardized mean difference of NLR in subjects with CRP ≤11 mg/L (0.57, 95% CI 0.36-0.78, P < 0.001; I 2 = 57.9%, P = 0.036) was lower than that of patients with CRP > 11 mg/L (0.71, 95% CI 0.48-0.93, P < 0.001; I 2 = 77.2%, P < 0.0001, Figure 4 ), although the differences were not statistically significant in meta-regression analysis (P = 0.42).
Similarly, SMD of NLR values in subjects with ESR ≤37 mm/h (0.53, 95% CI 0.38-0.68, P < 0.001; I 2 = 39.3%, P = 0.144) was lower than that of patients with ESR > 37 mm/h (0.75, 95% CI 0.55-0.99, P < 0.001; I 2 = 73.7%, P < 0.001, Figure 4 ), although the differences were not statistically significant in meta-regression analysis (P = 0.42). Furthermore, SMD of NLR was lower in prospective studies (0.57, 95% CI 0.31-0.83, P < 0.001; I 2 = 76.4%, P = 0.001) when compared to retrospective studies (0.71, 95% CI: 0.53-0.89, P < 0.001; I 2 = 61.1%, P = 0.025, Figure 4 ). However, once again, the differences were not statistically significant in meta-regression (P = 0.39). Finally, after classifying the studies according to the country, the five studies performed in China showed a higher SMD (0.76, 95% CI 0.52-1.00, P < 0.001; I 2 = 76.1%, P = 0.002) when compared to six studies conducted in Turkey (0.55, 95% CI: 0.37-0.73, P < 0.001; I 2 = 54.5%, P = 0.051, Figure 4 ). The differences were not statistically significant in meta-regression (P = 0.21).
| PLR and rheumatoid arthritis
Eight studies evaluated PLR [6] [7] [8] [9] 11, 14, 15, 33 in a total of 380 RA patients (203 males and 177 females) and 305 healthy controls (149 males and 156 females). The mean ± SD age of RA patients and controls was 39.7 ± 6.8 and Figure 5 . The PLR values were consistently higher in RA patients than in controls. Due to the high heterogeneity between studies (I 2 = 77.1%, P < 0.001), random-effects models were used. Overall, pooled results showed that PLR values were significantly higher in patients with RA (SMD = 0.66, 95% CI 0.43-0.88; P < 0.001).
Results stability was evaluated through sensitivity analysis ( Figure 6 ). The corresponding pooled SMD values were not substantially altered when single studies were removed (SMD range: 0.57-0.72), suggesting that the results of the meta-analysis were stable ( Figure 6 ). Bias analysis indicated the absence of publication bias (Begg's test P = 0.90 and Egger tests P = 0.87). No potentially missing studies were detected by the trim-and-fill method.
Similarly, to NLR, we investigated the effects of different disease severity (CRP ≤12 vs >12 mg/L and ESR ≤38 vs >38 mm/h) and study types (retrospective or prospective) on SMD values.
Standardized mean difference of PLR in subjects with CRP ≤12 mg/L (0.57, 95% CI 0.31-0.84, P < 0.001; I 2 = 52.1%, P = 0.099) was lower than that of patients with CRP > 12 mg/L (0.74, 95% CI 0.37-1.11, P < 0.001; I 2 = 87.3%, P < 0.001, Figure 7 ), although the differences were not statistically significant in meta-regression analysis (P = 0.50). Moreover, pooled differences of PLR values in subjects with ESR ≤38 mm/h (0.51, 95% CI 0.25-0.78, P < 0.001; I 2 = 68.9%, P = 0.022) were lower than that of patients with ESR > 38 mm/h (0.81, 95% CI 0.52-1.11, P < 0.001; I 2 = 70.1%, P = 0.018, Figure 7 ), although the differences were not statistically significant in meta-regression analysis (P = 0.19). Furthermore, SMD of PLR was higher in prospective studies (0.74, 95% CI 0.38-1.11, P < 0.001; I 2 = 78.9%, P = 0.003) when compared to retrospective studies (0.58, 95% CI: 0.30-0.85, P < 0.001; I 2 = 72.9%, P = 0.011, Figure 7 ). However, once again, the differences were not statistically significant in metaregression (P = 0.50). Finally, classifying the studies according to the country the four studies performed in China showed a higher SMD (0.89, 95% CI 0.66-1.12, P < 0.001; I 2 = 62.6%, P = 0.045) when compared to the three studies conducted in Turkey (0.37, 95% CI: 0.21-0.53, P < 0.001; I 2 = 0.0%, P = 0.83, Figure 7 ). The differences were statistically significant in meta-regression analysis (P = 0.02).
In some studies included in the meta-analysis, case and controls were not accurately matched for gender and age. [7] [8] [9] [10] 13, 16 However, meta-regression analysis indicated that pooled SMD of NLR and PLR were not related with age (t = −0.30, P = 0.77 and t = 0.32, P = 0.76, respectively) or gender (t = −0.81, P = 0.43 and t = 0.33, P = 0.75, respectively). 4 | DISCUSSION Neutrophils, lymphocytes and platelets have a significant role in the control of inflammation in RA and their peripheral blood levels are widely used as a surrogate measure of disease activity. However, the complex pathophysiology of neutrophils, platelets and monocytes, and their mutual interactions, is closely linked to the pathogenetic, immunemediated, mechanisms of disease, rather than simply indicating the inflammatory state in RA.
F I G U R E 2 Forest plot of studies examining neutrophil-to-lymphocyte ratio (NLR) and rheumatoid arthritis (RA)
RA pathogenesis is largely based on dysregulated activity of both B and T cells: B-T cell interaction promotes the activation and differentiation of plasma cells with production of autoantibodies. Activated B cells support effector T-cells differentiation and production of proinflammatory cytokines. 1 Neutrophils are thought to be key players in the pathogenesis of RA, 34 given their involvement in the activation of antigen-presenting cells 35 and production of pro-oxidative mediators and lytic enzymes in the joint micro-environment. Of interest, very recently a crucial role in the dysregulation of the adaptive response of the immune system has been attributed to the release by RA neutrophils of neutrophil extracellular traps (NETs) containing high amounts of citrullinated proteins. 36, 37 The role of platelets in the pathogenesis of RA appears to be more controversial. 38 Zamora et al 39 demonstrated an
anti-inflammatory role of platelets mediated by platelet- leucocyte (lymphocytes, monocytes and macrophages) cellto-cell interactions via P-selectin, platelet glycoprotein Ibα (GPIbα) and CD40L. Conversely, Boilard et al 40 proposed a pro-inflammatory role for platelets in RA by leucocyte recruitment into the synovial vascular compartment. The NLR and PLR, easily derived from the complete blood count, may closely reflect underlying RA pathogenetic pathways as well as disease progression and severity. This aspect is potentially relevant, considering that, despite a rapidly growing knowledge about interleukins, cytokines and serum autoantibodies in RA, there is an ongoing need to identify better diagnostic markers than traditional measures of systemic inflammatory burden such as CRP and ESR.
This meta-analysis showed significant associations between peripheral blood NLR and PLR and the presence of RA. Although our findings are consistent with those of a previous meta-analysis by Hao et al, 21 reporting a SMD of 0.75 (95% CI: 0.23-1.28) and 33.91 (95% CI: 20.50-47.32) for NLR and PLR, respectively, they include a larger number of studies (13 vs 3). Additionally, we performed subgroup analysis sensitivity analysis and metaregression to identify potential sources of significant heterogeneity observed across studies. Studies performed in RA patients with a lower degree of systemic inflammation demonstrated reduced heterogeneity with respect to those performed in RA series with higher inflammation, although this difference did F I G U R E 6 Sensitivity analysis (A) and funnel plot (B) of studies examining platelet-to-lymphocyte ratio (PLR) and rheumatoid arthritis (RA) not reach statistical significance. Although differences in study design (prospective vs retrospective) can potentially account for inconsistency among studies this did not significantly affect heterogeneity in our meta-analysis. Analysis of the country location of the study as a source of heterogeneity did not appear to explain heterogeneity for NLR. Conversely, we found a significant difference in the heterogeneity of studies reporting PLR according to country location, with studies performed in Turkey demonstrating no heterogeneity (I 2 = 0.0%) compared to studies performed in China (I 2 = 62.6%): factors potentially explaining this geographical difference include subject's ethnicity and/or specific sample collection and processing techniques. As depicted in forest plot and funnel plot (Figure 2A ,C) one NLR study represented an outlier, 16 primarily because of its relatively low SD values compared to other studies. However, the heterogeneity was not significantly affected by removing this study from the analysis.
Although meta-analyses generally enhance the quality of the available evidence, inherent limitations of our study should be acknowledged. First, non-English language studies were excluded, which might have biased conclusions. Secondly, the impact of specific immunosuppressive drugs (non-steroidal anti-inflammatory drugs, glucocorticoids, synthetic and biologic disease modifying anti-rheumatic drugs) on NLR and PLR was not assessed due to the lack of data provided in individual studies. This issue needs to be addressed in future studies evaluating haematological parameters in RA given the known influence of several immunomodulating drugs on circulating blood cells. Thirdly, the role of NLR and PLR as markers of RA disease severity (measured by Disease Activity Score-28 joints, DAS-28) was not investigated due to the relatively low number of relevant studies and the high heterogeneity in cut-offs used. 8, 9, 13, 15, 33 Lastly, the assessment of NLR and PLR according to RF and ACPA positivity was not performed for similar reasons.
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F I G U R E 7
Forest plots depicting the standardized mean difference (SMD) of platelet-to-lymphocyte ratio (PLR) between controls and rheumatoid arthritis (RA) according to inflammatory markers (A, B), study design (C) and country (D)
